Silence Therapeutics Plc American Depository Share (SLN)

FairStock Score: 21/100 — RISKY

Key Financials

AI Analysis

AI-generated, general educational analysis — not personal investment advice.

Mr. Market is quoting this pre-profit siRNA developer at $8.87 per ADS, a $369.8M market cap at the close on 2026-10-13. The company has 88 employees and a pipeline in hematology, cardiovascular, and rare diseases. But a pipeline is not a moat until trials and commercialization prove it. The filed figures show the financial reality: in FY2023, revenue was $31.6M and net loss was $54.2M; in FY2024, revenue was $43.3M and net loss was $45.3M; in FY2025, revenue fell to $559,000 and net loss widened to $88.6M. In fiscal Q1 2026, the quarter ended 2026-03-31, revenue was $422,000 and net loss was $15.0M. In fiscal Q2 2026, the quarter ended 2026-06-30, no revenue was reported and net loss was $12.3M. FairStock's calculations show P/E -6.88, P/B 10.95, ROE -90.41%, ROCE -29.65%, FCF yield -11.4%, Piotroski 5/9, Altman Z-score -4.06, and FairStock Score 21/100. Debt/equity is 0.00, which is a small mercy, but cash burn is the dominant fact. The Lynch category is none because losses occurred in each of the last four years. Graham would want assets or earnings power as a margin of safety; here the value depends on future clinical outcomes. I see a speculative biotech option, not a proven compounding business.

In plain English: Silence Therapeutics is a small biotech with 88 employees developing RNA-based medicines for blood, heart, and rare diseases. It is not yet a profitable business: filed results show a net loss of $88.6 million in fiscal 2025 and only $559,000 of revenue that year. Because it loses money and has very little sales, the shares look speculative and not obviously cheap on the numbers.

The full AI analysis, bull and bear case and key monitorables are in FairStock Pro.

Data as of 2026-10-13 close · note generated 2026-10-15 · model deepseek-flash

Sources (SEC EDGAR): fiscal Q2 2026 10-Q (period ended 2026-06-30) · fiscal Q1 2026 10-Q (period ended 2026-03-31) · fiscal Q3 2025 10-Q (period ended 2025-09-30) · fiscal Q2 2025 10-Q (period ended 2025-06-30) · FY2025 10-K (period ended 2025-12-31) · FY2024 10-K (period ended 2024-12-31) · FY2023 10-K (period ended 2023-12-31)

Fundamentals from company filings and market-data providers; prices are end-of-day, not real-time. AI-generated analysis is general and educational — not personal investment advice. Scoring methodology · Score test · Disclaimer